EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Adjudicating Heart Failure Events in Participants Receiving Hemodialysis: Findings from Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events (EVOLVE) Trial

Guson Kang, Safa Abdalla, Patrick S Parfrey, Renato D Lopes, Uptal D Patel, Gerard London, Glenn M Chertow, Kenneth W Mahaffey

American Journal of Nephrology · 19.06.2026 · 1-9

DOI: 10.1159/000553103 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Nephrology, online erschienen am 19.06.2026. Verfasst von Guson Kang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Stanford Center for Clinical Research, Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford,…. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events (EVOLVE) trial compared the effects of cinacalcet against placebo on major cardiovascular events in 3,883 hemodialysis patients with secondary hyperparathyroidism. In this manuscript, we describe heart failure events in EVOLVE and the role of centralized adjudication on heart failure reporting.

Methods

A central clinical events classification committee (CEC) defined and adjudicated suspected heart failure events reported by the site investigators. The treatment effect was analyzed by intention to treat.

Results

Overall, 3,883 participants were enrolled, 1,366 heart failure events were reported by site investigators, and 40 potential events were identified independently by the CEC. Among site investigator-reported events, 653 (47.8%) were adjudicated by the CEC as heart failure endpoints. Of the 40 potential events identified independently by the CEC, 17 (42.5%) were adjudicated as heart failure endpoints. The effect of cinacalcet compared with placebo on time to first heart failure event using CEC-adjudicated and site investigator-reported events (10.6% and 12.2% for CEC-adjudicated events [relative hazard 0.82, 95% CI: 0.68–0.99] and 20.3% and 22.1% for site investigator-reported events [relative hazard 0.88, 95% CI: 0.77–1.01]) was similar, although CEC data included fewer events but nominally statistically significant results.

Conclusion

Roughly half of heart failure events reported by site investigators were not adjudicated as heart failure by the CEC. Site investigators failed to report additional events that were later adjudicated as heart failure endpoints. These findings suggest that, in the hemodialysis population, identifying and classifying heart failure events is challenging and highlight the importance of centralized adjudication to ensure specificity and consistency in clinical events ascertainment.

Schlagwörter

Stichwörter der Autor:innen

AdjudicationCinacalcetClinical trialHeart failureHemodialysis

Autor:innen und Institutionen

  • Stanford Center for Clinical Research, Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California, USA.
  • Department of Medicine, Division of Nephrology, Stanford University School of Medicine, Stanford, California, USA.
  • Faculty of Medicine, Memorial University of Newfoundland, St. John's, Newfoundland, Canada.
  • Duke University Medical Center, Department of Medicine, Division of Cardiology, Duke Clinical Research Institute, Durham, North Carolina, USA.
  • European Renal Association and European Dialysis and Transplant Association, London, UK.
  • Stanford Center for Clinical Research, Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California, USA, kmahaf@stanford.edu.

Zitieren

APA

Kang, G., Abdalla, S., Parfrey, P. S., Lopes, R. D., Patel, U. D., London, G., Chertow, G. M., & Mahaffey, K. W. (2026). Adjudicating Heart Failure Events in Participants Receiving Hemodialysis: Findings from Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events (EVOLVE) Trial. American Journal of Nephrology, 1-9. https://doi.org/10.1159/000553103

Vancouver

Kang G, Abdalla S, Parfrey PS, Lopes RD, Patel UD, London G, et al. Adjudicating Heart Failure Events in Participants Receiving Hemodialysis: Findings from Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events (EVOLVE) Trial. American Journal of Nephrology. 2026:1-9. doi:10.1159/000553103

BibTeX
@article{Kang2026,
  author = {Kang, Guson and Abdalla, Safa and Parfrey, Patrick S and Lopes, Renato D and Patel, Uptal D and London, Gerard and Chertow, Glenn M and Mahaffey, Kenneth W},
  title = {Adjudicating Heart Failure Events in Participants Receiving Hemodialysis: Findings from Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events (EVOLVE) Trial},
  journal = {American Journal of Nephrology},
  year = {2026},
  pages = {1--9},
  doi = {10.1159/000553103}
}
Kostenlos starten →